Merck Presents 5-Year Adjuvant Melanoma Data for Keytruda Showing Durable Benefit

Merck today announced 5-year follow-up data from the Phase 3 KEYNOTE-716 trial showing that KEYTRUDA (pembrolizumab) provides durable recurrence-free survival benefit in patients with resected stage IIB or IIC melanoma. At 5 years, the RFS rate was 72.4% for KEYTRUDA versus 59.3% for placebo. The distant metastasis-free survival rate was 78.2% for KEYTRUDA versus 67.1% for placebo. These results demonstrate the long-term benefit of adjuvant KEYTRUDA in stage IIB/IIC melanoma and support its use as the standard of care in this setting.